Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grainne Kerr

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Molecular Cancer Therapeutics|August 5, 2020
The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal MelanomaFlorencia Rago, GiNell Elliott, Ailing Li, et al.
Cancer Research|August 24, 2018
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, et al.
Nature Medicine|September 13, 2022
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF<sup>V600E</sup> metastatic colorectal cancerElena Elez, Javier Ros, Jose Fernández, et al.
Nature|July 2, 2025
Author Correction: Targeting the SHOC2-RAS interaction in RAS-mutant cancersZachary J Hauseman, Frédéric Stauffer, Kim S Beyer, et al.
Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.
Nature|May 7, 2025
Targeting the SHOC2-RAS interaction in RAS-mutant cancersZachary J Hauseman, Frédéric Stauffer, Kim S Beyer, et al.
Nature|April 24, 2024
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancersStephane Ferretti, Jacques Hamon, Ruben de Kanter, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Molecular Cancer Therapeutics|August 5, 2020
The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal MelanomaFlorencia Rago, GiNell Elliott, Ailing Li, et al.
Cancer Research|August 24, 2018
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, et al.
Nature Medicine|September 13, 2022
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF<sup>V600E</sup> metastatic colorectal cancerElena Elez, Javier Ros, Jose Fernández, et al.
Nature|July 2, 2025
Author Correction: Targeting the SHOC2-RAS interaction in RAS-mutant cancersZachary J Hauseman, Frédéric Stauffer, Kim S Beyer, et al.
Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.
Nature|May 7, 2025
Targeting the SHOC2-RAS interaction in RAS-mutant cancersZachary J Hauseman, Frédéric Stauffer, Kim S Beyer, et al.
Nature|April 24, 2024
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancersStephane Ferretti, Jacques Hamon, Ruben de Kanter, et al.
Pageof 3